Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: John S. Baker who wrote (385)	9/12/1998 12:15:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 586

Hi John, Tough to figure out what's going on these days. Are we not suppose to hear about the FDA's decision to either review the PMA application by October vs. Feb '99 soon?? The volume may just be the Aries fund or Allen Co. buying up monthly blocks. It seems to me that this may be a good time to buy more. The price has been hurt in part due to all the general market turmoil. Assuming FDA approval, this time may prove to be a real bargain.

To: John S. Baker who wrote (385)	9/16/1998 9:00:00 AM
From: brent gephart	Respond to of 586

FDA Advisory Panel to Review Prosorba Column for Use in Rheumatoid Arthritis Company Announces Completion of Private Placement (Quick reference to the specifics.) SAN DIEGO--(BW HealthWire)--Sept. 16, 1998--Cypress Bioscience, Inc. (NASDAQ:CYPB - news) announced today that a U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Device Advisory Panel will review the Company's application to extend labeling of its Prosorba(R) column for use in rheumatoid arthritis (RA) at its October 29, 1998 meeting. The Prosorba(R) column has been FDA approved since 1987 for the treatment of Idiopathic Thrombocytopenic Purpura (ITP), an immune-mediated bleeding disorder. Private Placement Completed to Support Product Launch Independently, Cypress announced today that it had raised $3.3MM in a private placement of 2,180,000 Series A Preferred Stock, convertible on a one-to-one basis into common shares. The investors included both current, significant stockholders of the Company as well as some new institutional investors. The Company believes that this money, combined with its current resources, will be sufficient to launch the Prosorba(R) column for RA.